About
Small Molecule, peptides, antibody therapies, contract analytical
Areas of Focus
Categories
Biologics & BiopharmaceuticalVaccineSmall Molecule PharmaceuticalGene Therapy, RNA & Peptide TherapyAntibodyJapan
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
217
By Phase
PHASE1: 6PHASE1/PHASE2: 1
By Status
TERMINATED: 3COMPLETED: 2UNKNOWN: 1ACTIVE_NOT_RECRUITING: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
Today
Hover over trial bars to see details
Recent Trials
NCT04176016Lead Sponsor
Phase I Study of Radiolabeled OTSA101-DTPA in Patients With Relapsed or Refractory Synovial Sarcoma
PHASE1Terminated
12 participants
Started: Jan 10, 2020 · Completed: Jan 11, 2024
NCT03784040Collaborator
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
PHASE1Unknown
40 participants
Started: Feb 21, 2019 · Completed: Mar 1, 2024
NCT02926690Lead Sponsor
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
PHASE1Active, not recruiting
70 participants
Started: May 29, 2017 · Completed: Sep 30, 2027
NCT02795520Lead Sponsor
Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia
PHASE1/PHASE2Terminated
32 participants
Started: Apr 30, 2016 · Completed: Sep 30, 2021
NCT02768519Lead Sponsor
Study to Evaluate Systemic Bioavailability of Oral OTS167 in Healthy Adult Subjects
PHASE1Completed
11 participants
Started: Jan 31, 2016 · Completed: Feb 29, 2016
Locations (1)
Headquarters
Kawasaki, Japan
Map
Loading map...